

# CITATION REPORT

List of articles citing

## Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study

DOI: 10.1002/jcph.1362

Journal of Clinical Pharmacology, 2019, 59, 702-716.

**Source:** <https://exaly.com/paper-pdf/74563642/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. <i>Future Oncology</i> , <b>2019</b> , 15, 3267-3281	3.6	14
19	Trastuzumab/Hyaluronidase-oysk: A New Option for Patients With HER2-Positive Breast Cancer. <i>Annals of Pharmacotherapy</i> , <b>2020</b> , 54, 254-261	2.9	4
18	A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers. <i>Current Therapeutic Research</i> , <b>2020</b> , 93, 100604	2.4	4
17	Injectables and Depots to Prolong Drug Action of Proteins and Peptides. <i>Pharmaceutics</i> , <b>2020</b> , 12,	6.4	11
16	2. Therapie des metastasierten Mammakarzinoms. <b>2020</b> , 71-120		
15	Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology</i> , <b>2021</b> , 22, 85-97	21.7	24
14	Flexible care in breast cancer. <i>ESMO Open</i> , <b>2021</b> , 6, 100007	6	4
13	Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Clinical Pharmacology in Drug Development</i> , <b>2021</b> , 10, 1142-1155	2.3	4
12	Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 88, 100-110	3.5	2
11	Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta <sup>®</sup> in Healthy Chinese Male Volunteers. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 660541	5.6	0
10	Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , <b>2021</b> , 61, 1096-1105	2.9	0
9	Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery. <i>Expert Opinion on Drug Delivery</i> , <b>2021</b> , 18, 1673-1685	8	0
8	A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta <sup>®</sup> in healthy Chinese male subjects. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 1-9	5.4	0
7	Patient Centricity Driving Formulation Innovation: Improvements in Patient Care Facilitated by Novel Therapeutics and Drug Delivery Technologies.. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2022</b> , 62, 341-363	17.9	1
6	Formulation and device lifecycle management of biotherapeutics leveraging synergies across therapeutic areas. <b>2022</b> , 153-174		
5	Enabling a flexible care setting in oncology flow to realize home- and self-administration of biotherapeutics in cancer care. <b>2022</b> , 107-151		
4	Dual-detection approach for charge variant analysis of monoclonal antibody combination products using imaged capillary isoelectric focusing. <i>Electrophoresis</i> ,	3.6	

3	Advanced Formulations/Drug Delivery Systems for Subcutaneous Delivery of Protein-Based Biotherapeutics. <b>2022,</b>	0
2	Pharmacokinetic characterization, benefits and barriers of subcutaneous administration of monoclonal antibodies in oncology. 107815522211377	1
1	Drug delivery improvements to enable a flexible care setting for monoclonal antibody medications in oncology - Analogue-based decision framework. 1-14	0